

## SPECIALTY GUIDELINE MANAGEMENT

### SIMPONI (golimumab for subcutaneous injection)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

1. Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate
2. Active psoriatic arthritis (PsA)
3. Active ankylosing spondylitis (AS)
4. Moderately to severely active ulcerative colitis (UC)

###### B. Compendial Uses

- A. Axial spondyloarthritis

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. CRITERIA FOR INITIAL APPROVAL

###### A. **Moderately to severely active rheumatoid arthritis (RA)**

1. Authorization of 24 months may be granted for members who have received Simponi or any other biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz) indicated for moderately to severely active rheumatoid arthritis in a paid claim through a pharmacy or medical benefit in the previous 120 days of the initial request for Simponi. Simponi must be prescribed in combination with methotrexate unless the member has a contraindication or intolerance to methotrexate (see Appendix A).
2. Authorization of 24 months may be granted for treatment of moderately to severely active RA when all of the following criteria are met:
  - a. Member is prescribed Simponi in combination with methotrexate or has a contraindication or intolerance to methotrexate.
  - b. Member meets any of the following criteria:
    - o Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week).
    - o Member has an intolerance or contraindication to methotrexate.

###### B. **Active psoriatic arthritis (PsA)**

Authorization of 24 months may be granted for treatment of active psoriatic arthritis (PsA).

###### C. **Active ankylosing spondylitis (AS) and axial spondyloarthritis**

1. Authorization of 24 months may be granted for members who have received Simponi or any other biologic DMARD indicated for active ankylosing spondylitis in a paid claim through a pharmacy or medical benefit in the previous 120 days of the initial request for Simponi.

2. Authorizations of 24 months may be granted for treatment of active ankylosing spondylitis and axial spondyloarthritis when any of the following criteria is met:
  - a. Member has experienced an inadequate response to at least two non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period in total at maximum recommended or tolerated anti-inflammatory dose.
  - b. Member has an intolerance and/or contraindication to two or more NSAIDs (see Appendix B).

**D. Moderately to severely active ulcerative colitis (UC)**

1. Authorization of 24 months may be granted for members who have received Simponi or any other biologic indicated for moderately to severely active ulcerative colitis in a paid claim through a pharmacy or medical benefit in the previous 120 days of the initial request for Simponi.
2. Authorization of 24 months may be granted for treatment of moderately to severely active UC when any of the following criteria is met:
  - a. Member has corticosteroid dependence as evidenced by any of the following:
    - i. Member requires continuous corticosteroid therapy.
    - ii. Corticosteroids cannot be successfully tapered without a return of ulcerative colitis symptoms.
  - b. Member has an inadequate response, intolerance or contraindication to at least one conventional therapy option (see Appendix C).

**III. CONTINUATION OF THERAPY**

Authorization of 24 months may be granted for all members (including new members) who meet all initial authorization criteria and achieve or maintain positive clinical response after at least 3 months of therapy with Simponi as evidenced by low disease activity or improvement in signs and symptoms of the condition.

**IV. OTHER**

For all indications: Member has a pretreatment tuberculosis (TB) screening with a TB skin test or an interferon gamma release assay (e.g., QFT-GIT, T-SPOT.TB).

Note: Members who have received Simponi or any other biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz) in a paid claim through a pharmacy or medical benefit in the previous 120 days of the continuation request are exempt from requirements related to TB screening in this Policy.

**V. APPENDICES**

**Appendix A: Examples of Contraindications to Methotrexate**

1. Alcoholism, alcoholic liver disease or other chronic liver disease
2. Breastfeeding
3. Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia)
4. Elevated liver transaminases
5. History of intolerance or adverse event
6. Hypersensitivity
7. Interstitial pneumonitis or clinically significant pulmonary fibrosis
8. Myelodysplasia
9. Pregnancy or planning pregnancy (male or female)
10. Renal impairment
11. Significant drug interaction

**Appendix B: Examples of Contraindications to the Use of NSAIDs**

1. Allergic-type reaction following aspirin or other NSAID administration
2. Asthma
3. Gastrointestinal bleeding
4. History of intolerance or adverse event
5. Significant drug interaction
6. Urticaria

**Appendix C: Examples of Conventional Therapy Options for UC**

1. Mild to moderate disease – induction of remission:
  - a. Oral mesalamine (e.g., Asacol, Asacol HD, Lialda, Pentasa), balsalazide, olsalazine
  - b. Rectal mesalamine (e.g., Canasa, Rowasa)
  - c. Rectal hydrocortisone (e.g., Colocort, Cortifoam)
  - d. Alternatives: prednisone, azathioprine, mercaptopurine, sulfasalazine
2. Mild to moderate disease – maintenance of remission:
  - a. Oral mesalamine, balsalazide, olsalazine, rectal mesalamine
  - b. Alternatives: azathioprine, mercaptopurine, sulfasalazine
3. Severe disease – induction of remission:
  - a. Prednisone, hydrocortisone IV, methylprednisolone IV
  - b. Alternatives: cyclosporine IV, tacrolimus, sulfasalazine
4. Severe disease – maintenance of remission:
  - a. Azathioprine, mercaptopurine
  - b. Alternative: sulfasalazine
5. Pouchitis: Metronidazole, ciprofloxacin
  - a. Alternative: rectal mesalamine

**VI. REFERENCES**

1. Simponi [package insert]. Horsham, PA: Janssen Biotech, Inc.; January 2016.
2. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis*. 2011;70:905-908.
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. *Ann Rheum Dis*. 2014;73:492-509.
4. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum*. 2008;59(6):762-784.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
7. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies; 2015 update. *Ann Rheum Dis*. 2016;75(3):499-510.
8. Gladman DD, Antoni C, P Mease, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005;64(Suppl II):ii14–ii17.
9. Peluso R, Lervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritis patients. [Published online ahead of print May 8, 2014]. *Clin Rheumatol*. 2014. Accessed August 22, 2014.
10. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*. 2011;70:896–904.

11. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2015: 10.1002/art.39298. [Epub ahead of print].
12. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. *Am J Gastroenterol*. 2011;106(Suppl 1):S2-S25.